Skip to content
lifestyle.buyersdesire.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Candel Therapeutics
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 14, 2026
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
March 14, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2026
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
March 11, 2026
Candel Therapeutics Announces Pricing of Public Offering
March 11, 2026
Candel Therapeutics Announces Proposed $100 Million Public Offering
March 11, 2026
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
March 11, 2026
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
March 9, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2026
←
Previous Page
1
2